Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...

Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being ...

A new portable device developed by Rutgers University researchers can detect genetic mutations linked to hereditary ...

Carpal tunnel syndrome severely affects your quality of life and capacity to do day-to-day tasks. But can it also be a hint ...

Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Aortic valve narrowing (aortic stenosis) with concomitant cardiac amyloidosis is a severe heart disease of old age that is ...

The interim data, with a cutoff date of April 11, 2025, showed an impressive 70% CR rate. Prior to NXC-201 treatment, the ...

Prothena has already discontinued the development of birtamimab, and anticipates further spending cuts, including workforce ...

Prothena has made the decision to discontinue the AFFIRM-AL trial, including the open-label extension portion.

Prothena halts birtamimab development after Phase 3 trial fails to meet endpoints in AL amyloidosis patients; cost cuts and ...